Defendant Name:
Northwest Biotherapeutics, Inc.
Defendant Type:
Public Company
SIC Code:
2834
CUSIP:
66737P60
Document Reference:
34-87281
Document Details
Legal Case Name
In the Matter of Northwest Biotherapeutics, Inc.
Document Name
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing and Cease-and-Desist Order
Document Date
10-Oct-2019
Document Format
Administrative Proceeding
AAER
4099
Allegation Type
Issuer Reporting and Disclosure
Document Summary
On October 10, 2019, the SEC instituted settled cease-and-desist proceedings against Northwest Biotherapeutics, Inc. ("Respondent"). The SEC stated: "These proceedings involve violations of the federal securities laws in connection with the Respondent's Internal Control over Financial Reporting ("ICFR"). Respondent failed to create and implement effective ICFR for twelve consecutive annual reporting periods from 2007 through 2018."
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Compliance Related Independent Consultant
Other Compliance Related Undertaking
Certify compliance with Undertakings to SEC
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:
Civil Penalty
Individual:
$250,000.00
Shared: